

**Green Shield Prepaid Services Inc.**

Benefits/coverage, 6:81  
 Canadian Automobile Workers Union connection, 14:26-7  
 Legislation, Bill C-22 impact, 6:87  
 See also Drugs and pharmaceuticals—Costs/prices; Witnesses

**Gross National Product** see Drugs and pharmaceuticals industry—Research and development

**Group Surgical-Medical Insurance Plan**

Drug cost differential, Bill C-22 increasing, 11:54  
 See also Public Service Alliance of Canada

**Gunter, Dr. Avril** (Multiple Sclerosis Society of Ottawa-Carleton)  
 Patent Act (amdt.)(Bill C-22), 8:3, 5-16

**Haddad, Bill** see Drugs and pharmaceuticals industry—Compulsory licensing—Research and development, Development costs

**Hall Royal Commission**, 3:7, 68; 6:28, 49; 9:30

**Hamel, R.B.** (Canadian Chamber of Commerce)  
 Patent Act (amdt.)(Bill C-22), 8:3, 17, 19-21, 26-7

**Hanmer, Herbert** (National Pensioners and Senior Citizens Federation; United Senior Citizens of Ontario)  
 Patent Act (amdt.)(Bill C-22), 8:4; 15:3, 63

**Harley report**, 3:7, 68-9  
 See also Bill C-22—References, Background

**Hawkes, Jim** (PC—Calgary West)

Brand name drugs, 9:18-9, 49; 11:50-1, 62  
 Community Health Co-operative Federation of Saskatchewan, 11:78-80  
 Cystic fibrosis, 9:17-8  
 Drug Prices Review Board, 11:63  
 Drugs and pharmaceuticals, 9:50; 11:62-3  
 Drugs and pharmaceuticals industry, 9:19, 50-1; 11:64  
 Generic drugs, 9:18-9  
 Health care, 9:31, 38; 11:63-4  
 Medical journals, Canadian, 9:48-9  
 National Federation of Nurses' Unions, 9:36-8  
 Ontario Medical Reform Group, 9:48-9  
 Patent Act (amdt.)(Bill C-22), 9:17-20, 31, 36-8, 43, 48-51; 11:50-1, 62-4, 69-70, 78-81  
 Polls, 11:62  
 Procedure and Committee business, bills, 11:81  
 Scientific Research Tax Credit Program, 9:19-20

**Health care**

Canada Health Act policy co-ordinating, 6:29  
 Epp position, Progressive Conservative Party, sacred trust violating, 12:67-9; 14:23; 15:22, 93  
 Community care programs, Bill C-22 affecting, 11:59  
 Compulsory licensing, effect, 13:44-5  
 See also Health care—Hospitals, Ontario  
 Costs, pharmaceuticals' share, 5%, 8:51; 9:32; 11:40, 47-8; 14:35, 43  
 Drugs, over-reliance/over-prescribing, curbing, nurses' role, etc., 9:33, 38, 48; 10:29-30  
 Quebec example, 12:19-20  
 World Health Organization report, 12:20  
 Erosion, Bill C-22 impact, 9:26-8, 32-3, 38-9; 11:52, 59; 12:25, 54  
 Manitoba experience, 9:29; 15:95  
 Two-tier system, developing, 11:52, 54, 58, 63-4  
**Hospitals**  
 Drug therapy alternatives, tuberculosis, stalazine examples, etc., 12:32, 40-1, 63-4; 14:35, 44-5, 75; 15:17  
 Generic drugs, extensive use, 9:31-2; 12:68; 15:17, 24  
 Global budgets, Bill C-22 effect, 11:55; 15:18-20, 22-4, 28-9, 54-5

**Health care—Cont.**

**Hospitals—Cont.**  
 Legislation, Bill C-22 opposing, 15:21  
 Non-ionic contrast media, prices increasing, 15:24, 29  
 Ontario, compulsory licensing, \$12 million savings, 15:21, 24, 27, 29-30  
 Quebec situation, 12:24-5; 15:26  
 Legislation, Bill C-22 importance, 1:27-8; 11:48  
 Cost/benefit perspective, 13:17, 23-5, 28; 14:18, 64-5  
 Ontario, budget, 12:41  
 See also Health care—Hospitals  
 Preventative, 12:68  
 Research and development, 15:52-3  
 Focus, excessive, public health alternatives, 9:43-4, 50-1  
 Strengthening, 3:45-6  
 United States comparison, 14:28, 32; 15:64-5  
 Universality, brand name drugs' contribution, etc., 3:43-4; 14:31  
 See also Canadian Medical Association; Drugs and pharmaceuticals—Tagamet/cimetidine; Drugs and pharmaceuticals industry—Research and development; Free trade, Canada-United States negotiations

**Heritage Medical Fund for Research**

Researchers, attracting, Hollenberg, etc., 5:45

**High technology centres**

Boulder, Colorado/Salt Lake City, Utah, comparison, 5:35  
 North Carolina research park, success, 5:42  
 Subsidies, incentives, 5:36, 39  
 Universities, importance, 5:34-7, 41-5  
 Western Canada economic development, Bill C-22 stimulating, 5:33-46  
 Compulsory licensing, investment disincentive, 5:36-40

**Hill, Wally**

References, 3:13

**Hoffman-LaRoche Limited**, 6:45

Compulsory licensing, effect, 15:32  
 Research centre closing, Quebec, 10:12

**Holiday, Dr. Michael** (Multiple Sclerosis Society of Ottawa-Carleton)  
 Patent Act (amdt.)(Bill C-22), 8:3, 10, 14, 16

**Hollenberg, Morley** see Heritage Medical Fund for Research

**Holmwood, Kit** (National Action Committee on the Status of Women)  
 Patent Act (amdt.)(Bill C-22), 12:3, 65-76

**Horner, Bob** (PC—Mississauga North)

Brand name drugs, 3:32; 5:22, 30-1  
 Ciba-Geigy Canada Ltd., 3:66  
 Drug Prices Review Board, 3:67; 5:22-3  
 Drugs and pharmaceuticals, 3:67  
 Drugs and pharmaceuticals industry, 3:31, 66  
 Generic drugs, 3:33, 66; 5:22  
 Patent Act (amdt.)(Bill C-22), 3:31-3, 39, 57, 66-7; 5:8-9, 22-3, 30-1  
 Procedure and Committee business  
 Motions, 5:8  
 Proceedings, M. (Dingwall), 5:9

**Hospitals** see Drug plans; Drugs and pharmaceuticals industry—Research and development, Universities; Health care

**Hughes, Debbie** (National Anti-Poverty Organization)  
 Patent Act (amdt.)(Bill C-22), 12:3, 54-64

**Hunsley, Terrance M.** (Canadian Council on Social Development)  
 Patent Act (amdt.)(Bill C-22), 6:3, 61-73